Abiomed, Inc., founded in 1981 by David Lederman, is a medical device technology company based in Danvers, Massachusetts. Operating as a subsidiary within Johnson & Johnson's MedTech segment, Abiomed specializes in the development and manufacturing of temporary external and implantable mechanical circulatory support devices. The company's core mission is to recover hearts and save lives through innovative cardiovascular medical implant devices, with a market focus on patients suffering from severe coronary artery disease and advanced heart failure.
Notable figures affiliated with Abiomed include Andrew Greenfield (President), Thorsten Siess (EVP and CTO), and Chuck Simonton (EVP and CMO). The company has achieved significant milestones, including generating a revenue of $1.032 billion in 2022 and supporting numerous patients with its Impella® heart pumps. Abiomed's impact is profound, offering minimally invasive treatment options that allow patients to regain the function of their native heart, thereby significantly improving patient outcomes and quality of life.
